Sudden decline in kidney function (hours to days) characterized by decreased glomerular filtration rate (GFR), accumulation of nitrogenous wastes (urea, creatinine), and fluid/electrolyte imbalances. Often triggered by ischemia-reperfusion injury, sepsis, or nephrotoxins, leading to tubular epithelial cell death, inflammatory infiltration, and potential progression to chronic kidney disease if resolution mechanisms fail.
Imagine the kidney as a 24-hour water treatment plant with millions of tiny filtration units (glomeruli and tubules). Each unit has workers (tubular epithelial cells) who pull back useful materials from the waste stream while letting toxins pass through. AKI is like a sudden power outage combined with a flood β the electricity cuts out (ischemia), workers die from oxygen deprivation, and when power returns (reperfusion), the surge causes electrical fires (oxidative stress and inflammation). Now emergency crews arrive: neutrophils burst in like firefighters who accidentally smash windows and damage infrastructure while trying to help. Macrophages follow as cleanup crews β some (M1) keep throwing debris around aggressively, while others (M2) actually start repairs. Meanwhile, dead worker cells (necrotic tubular epithelium) release their identification badges (DAMPs) into the streets, triggering more alarms and calling in more emergency crews, creating a vicious cycle. The plant's backup generator (HIF pathway) kicks on initially to help cells survive the low oxygen, but if it runs too long, it starts rewiring the whole building incorrectly (fibrosis). The difference between recovery and permanent shutdown (chronic kidney disease) depends entirely on whether the cleanup crews receive the "stand down and rebuild" signal from specialized mediators (SPMs like resolvins and protectins) or whether inflammation just keeps cycling until scar tissue takes over.
Phase 1: Ischemic Injury & Cell Death (0-6 hours)
- Reduced renal blood flow β hypoxia in S3 segment of proximal tubule (most metabolically active, furthest from arterial supply)
- ATP depletion β NaβΊ-KβΊ-ATPase failure β loss of cell polarity, cytoskeletal disruption, loss of brush border
- Intracellular CaΒ²βΊ overload β mitochondrial permeability transition β cytochrome c release β caspase activation
- Mixed necrosis and apoptosis of tubular epithelial cells
- HIF-1Ξ± stabilization (PHD enzymes inhibited by hypoxia) β upregulation of VEGF, EPO, glycolytic enzymes (initially protective)
Phase 2: Reperfusion Injury & Oxidative Stress (6-24 hours)
- Return of oxygenated blood β burst of reactive oxygen species (ROS) from damaged mitochondria and NADPH oxidase
- Xanthine oxidase (converted from dehydrogenase during ischemia) β superoxide and HβOβ production
- Lipid peroxidation β further membrane damage
- Endothelial dysfunction: loss of NO bioavailability, increased ET-1 (vasoconstriction), upregulation of adhesion molecules (ICAM-1, VCAM-1, P-selectin)
Phase 3: Inflammatory Cascade (1-3 days)
- DAMPs released from necrotic cells (HMGB1, ATP, mitochondrial DNA, histones) β bind to TLR4, TLR2, NLRP3
- TLR4 activation β MyD88 β NF-ΞΊB translocation β transcription of IL-1Ξ², IL-6, TNF-Ξ±, CXCL1, CXCL2
- NLRP3 inflammasome assembly β caspase-1 activation β cleavage of pro-IL-1Ξ² and pro-IL-18 to active forms
- Neutrophil infiltration (peak 12-24h): CXCL1/CXCL2 (via CXCR2) recruit neutrophils to tubules
- Neutrophils release elastase, MPO, reactive oxygen species β further tissue damage
- NETosis (neutrophil extracellular traps) β chromatin nets trap bacteria but also obstruct tubules
- Macrophage infiltration (peak 2-7 days): CCL2 (MCP-1) recruits monocytes via CCR2
- M1 macrophages (activated by IFN-Ξ³, TNF-Ξ±) β produce IL-12, iNOS, more ROS β pro-inflammatory
- Transition to M2 (if SPMs present): IL-10, TGF-Ξ², Arginase-1 β pro-repair
Phase 4: Tubular Obstruction & Back-leak
- Sloughed necrotic cells and debris β cast formation in tubular lumen β obstruction β increased intratubular pressure β reduced GFR
- Loss of tight junction integrity (ZO-1 disruption) β back-leak of filtrate into interstitium
- Afferent arteriolar vasoconstriction (angiotensin II, endothelin-1, decreased NO) β further GFR reduction
Phase 5: Resolution vs. Fibrosis (3-14 days)
- Resolution pathway (requires SPMs):
- Neutrophil apoptosis β phosphatidylserine exposure β "eat me" signals
- Efferocytosis by M2 macrophages via Mer tyrosine kinase, LRP1, integrins
- SPM production: RvD1, RvD2 (from DHA via 15-LOX) bind to ALX/FPR2, GPR32 β SOCS-mediated inhibition of NF-ΞΊB, reduced neutrophil infiltration, enhanced macrophage efferocytosis
- MaR1 (maresin 1) via LGR6 receptor β M2 polarization, phagocytosis of apoptotic cells, reduced fibrotic signaling
- Tubular epithelial cell regeneration from surviving cells and intrarenal progenitors (scattered cells in S3 segment, parietal epithelial cells)
- Matrix remodeling: balanced MMP activity, collagen turnover
- Fibrotic pathway (impaired resolution):
- Persistent M1 macrophages β continuous TGF-Ξ² secretion
- TGF-Ξ² β Smad2/3 phosphorylation β nuclear translocation β transcription of collagen I, III, fibronectin, Ξ±-SMA
- Epithelial-to-mesenchymal transition (EMT): tubular cells lose E-cadherin, gain vimentin, Ξ±-SMA β become fibroblasts
- Myofibroblast accumulation β collagen deposition β interstitial fibrosis
- Chronic HIF-1Ξ± activation (in areas of persistent hypoxia or genetic HIF stabilization) β VEGF β aberrant angiogenesis but also pro-fibrotic signaling (via HIF-TGF-Ξ² crosstalk)
- Outcome: progressive loss of functional nephrons β chronic kidney disease
graph TD
A[Ischemia] --> B[ATP Depletion]
B --> C[Tubular Cell Death]
C --> D[DAMP Release]
D --> E[TLR4/NLRP3 Activation]
E --> F["NF-ΞΊB β IL-1Ξ², TNF-Ξ±, IL-6"]
F --> G[Neutrophil Recruitment]
F --> H[Macrophage Recruitment]
I[Reperfusion] --> J[ROS Burst]
J --> K[Oxidative Stress]
K --> C
G --> L{Resolution Signals Present?}
H --> L
L -->|"Yes: SPMs RvD1/MaR1"| M[M2 Polarization]
M --> N[Efferocytosis]
N --> O[Tubular Regeneration]
O --> P[Recovery]
L -->|"No: Impaired Resolution"| Q[Persistent M1]
Q --> R["TGF-Ξ² Upregulation"]
R --> S[Fibroblast Activation]
S --> T[Collagen Deposition]
T --> U[Chronic Kidney Disease]
V["Chronic HIF-1Ξ±"] --> R
Patient Populations at Risk:
- Critically ill/ICU patients (40-50% incidence in septic shock)
- Post-cardiac surgery (5-30% depending on complexity)
- Contrast exposure in vulnerable patients (CKD, diabetes, dehydration)
- Rhabdomyolysis (myoglobin nephrotoxicity)
- Drug-induced: NSAIDs (afferent vasoconstriction), aminoglycosides, chemotherapy
Diagnostic Thresholds (KDIGO Criteria):
- Stage 1: Serum creatinine (SCr) increase β₯0.3 mg/dL within 48h OR increase to 1.5-1.9Γ baseline OR urine output <0.5 mL/kg/h for 6-12h
- Stage 2: SCr 2.0-2.9Γ baseline OR urine output <0.5 mL/kg/h for β₯12h
- Stage 3: SCr β₯3.0Γ baseline OR increase to β₯4.0 mg/dL OR urine output <0.3 mL/kg/h for β₯24h OR anuria β₯12h OR initiation of renal replacement therapy
cPNI Framework Connections:
- Metamodel 0 (Evolutionary Mismatch): Modern nephrotoxic exposures (NSAIDs, contrast agents, chemotherapy) far exceed ancestral kidney stressors; chronic hyperglycemia creates persistent hypoxia-like stress via pseudohypoxia
- Metamodel 5 (Inflammation-Resolution): AKI is a textbook example of resolution failure β patients who develop CKD have impaired SPM production, defective efferocytosis, and persistent M1 dominance
- Selfish Immune System: In severe AKI, the immune system prioritizes pathogen defense (neutrophil recruitment) over tissue preservation, accepting collateral damage as evolutionarily preferable to systemic infection
- Selfish Brain: Brain prioritizes its blood supply during shock states, potentially sacrificing renal perfusion (RAAS activation diverts flow to brain/heart)
Intervention Implications:
- Preventive: IV hydration before contrast (normal saline 1 mL/kg/h Γ 12h pre/post), N-acetylcysteine 600-1200mg BID (mild antioxidant effect), avoid NSAID+RAAS inhibitor+diuretic "triple whammy"
- Early AKI: Identify and reverse cause (stop nephrotoxins, fluid resuscitate if hypovolemic, treat sepsis), avoid further insults
- Resolution support: Omega-3 supplementation (EPA/DHA 2-4g/day) to provide SPM precursors, aspirin 81mg (triggers aspirin-triggered resolvin production via COX-2 acetylation), consider specialized pro-resolving mediators if available clinically
- Metabolic support: Avoid hyperglycemia (glucose >180 mg/dL worsens outcomes), adequate but not excessive protein (0.8-1.0 g/kg/day), electrolyte balance
- Monitor progression: Serial creatinine, urine output, biomarkers (NGAL, KIM-1 for earlier detection than creatinine), urinalysis for casts (muddy brown granular casts = acute tubular necrosis)
- Fibrosis prevention: If AKI severe/prolonged, aggressive resolution support, consider antifibrotic agents in research settings (pirfenidone, nintedanib off-label), avoid chronic RAAS activation
Mortality & Long-term Risk:
- In-hospital mortality: 10-20% (mild AKI) to 50-80% (severe AKI requiring dialysis in ICU)
- 25-50% of AKI survivors develop CKD within 1 year
- Even "recovered" AKI (creatinine returns to baseline) β 2-3Γ increased risk of future CKD, cardiovascular disease, and mortality (subclinical nephron loss and fibrosis)
- AKI defined by rapid GFR decline: β₯0.3 mg/dL SCr rise in 48h OR urine output <0.5 mL/kg/h for 6h
- S3 segment of proximal tubule most vulnerable (high metabolic demand, distal arterial supply)
- Ischemia-reperfusion injury generates ROS burst: xanthine oxidase + damaged mitochondria produce superoxide/HβOβ
- DAMP release (HMGB1, ATP, mtDNA) activates TLR4 β NF-ΞΊB β cytokine storm within 6-12h
- Neutrophil peak 12-24h post-injury; macrophage peak 2-7 days; resolution phase 3-14 days if SPMs present
- HIF-1Ξ± stabilization initially protective (anaerobic metabolism, VEGF), but chronic HIF β fibrosis via TGF-Ξ² crosstalk
- Failed resolution (low SPMs, impaired efferocytosis) β persistent M1 macrophages β TGF-Ξ² β myofibroblasts β collagen I/III deposition β CKD
- Biomarker timeline: NGAL rises 2-6h (earlier than creatinine), KIM-1 peaks 12-24h, creatinine lags 24-48h
- Omega-3 index <4% associated with worse AKI outcomes; >8% protective via SPM precursor availability
- "Triple whammy" (NSAID + RAAS inhibitor + diuretic) increases AKI risk 30-fold in vulnerable patients
- ischemia-reperfusion injury β primary pathogenic mechanism; ROS burst and endothelial dysfunction initiate cascade
- HIF-1Ξ± β dual role: acutely protective (anaerobic glycolysis, VEGF), but chronic stabilization drives fibrosis
- Specialized pro-resolving mediators (SPMs) β RvD1, RvD2, MaR1 terminate neutrophil infiltration, promote M2 polarization, enable tubular regeneration
- Resoleomics β measurement of SPM profiles predicts AKI recovery vs. CKD progression
- inflammation β TLR4/NLRP3-driven cytokine release recruits neutrophils and macrophages
- NF-ΞΊB β master transcription factor for IL-1Ξ², TNF-Ξ±, IL-6 production following DAMP recognition
- Efferocytosis β M2 macrophage clearance of apoptotic neutrophils via Mer, LRP1; impaired in CKD progression
- neutrophil β early infiltrators (12-24h) causing collateral damage via elastase, MPO, NETosis
- NETosis β neutrophil extracellular traps obstruct tubules, worsen inflammation
- Oxidative Stress β xanthine oxidase and mitochondrial ROS production during reperfusion phase
- mitochondrial dysfunction β ATP depletion, cytochrome c release, amplified ROS generation
- endothelial dysfunction β loss of NO, increased endothelin-1, adhesion molecule upregulation (ICAM-1, VCAM-1)
- Fibrosis β outcome of failed resolution; TGF-Ξ² β Smad2/3 β collagen I/III synthesis
- TGF-Ξ² β central pro-fibrotic cytokine; drives epithelial-to-mesenchymal transition and myofibroblast activation
- Chronic Kidney Disease β 25-50% of AKI survivors progress within 1 year due to subclinical nephron loss
- IL-1Ξ² β NLRP3 inflammasome product; drives fever, acute phase response, amplifies inflammation
- IL-6 β pro-inflammatory in early AKI (neutrophil recruitment), but also triggers resolution via STAT3 if SPMs present
- TNF-Ξ± β early cytokine (peak 2-6h) causing endothelial activation, apoptosis signaling
- DAMPs β HMGB1, ATP, mtDNA released from necrotic tubular cells activate TLR4/NLRP3
- TLR4 β recognizes HMGB1 and endotoxin; MyD88 pathway activates NF-ΞΊB
- NLRP3 β inflammasome assembly in response to ATP, ROS, crystalline material; cleaves pro-IL-1Ξ²
- M1 macrophages β pro-inflammatory phenotype (iNOS, IL-12); persist if resolution fails
- M2 macrophages β pro-repair phenotype (Arginase-1, IL-10); require SPM signaling for polarization
- CCL2 β monocyte chemoattractant (MCP-1); recruits macrophages to injured kidney
- CXCL1 β neutrophil chemoattractant; CXCR2 receptor mediates tubular infiltration
- RvD1 β resolvin D1 (from DHA + 15-LOX); binds ALX/FPR2 and GPR32 to stop neutrophil migration, enhance efferocytosis
- MaR1 β maresin 1; LGR6 receptor activates M2 program, reduces fibrosis
- DHA β docosahexaenoic acid (omega-3); substrate for D-series resolvins and neuroprotectins
- EPA β eicosapentaenoic acid (omega-3); substrate for E-series resolvins
- 15-LOX β lipoxygenase enzyme converting DHA to 17-HDHA (resolvin precursor)
- COX-2 β when acetylated by aspirin, produces aspirin-triggered resolvins (AT-RvD1)
- VEGF β HIF-1Ξ± target; promotes angiogenesis but also vascular permeability in AKI
- EPO β HIF-1Ξ± target; erythropoietin may have direct renal protective effects beyond erythropoiesis
- Insulin resistance β AKI induces acute systemic insulin resistance (stress hyperglycemia worsens outcomes)
- AGEs β advanced glycation end-products accumulate in CKD, crosslink collagen, worsen fibrosis
- Metabolic acidosis β common in AKI (reduced HβΊ excretion); worsens if progression to CKD
- Sepsis β leading cause of AKI in ICU (40% of septic shock); endotoxin/cytokines cause renal vasoconstriction
- RAAS β renin-angiotensin-aldosterone system activated in AKI; angiotensin II causes afferent vasoconstriction, worsens GFR
- Acute phase response β liver produces CRP, ferritin, hepcidin; hepcidin reduces iron availability (anemia of AKI)
- Hypoxia β tissue hypoxia persists in AKI due to microvascular dysfunction and reduced GFR
- ATP β depletion causes tubular cell death; extracellular ATP acts as DAMP via P2X7 receptors
- Autophagy β cellular cleanup mechanism; enhanced autophagy during ischemia may be protective, but excessive autophagy β cell death
- Module 5 (Resolution Pharmacology, HIF biology, SPMs, Efferocytosis)